Caredx announces preliminary fourth quarter and full year 2024 results

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ – today reported preliminary, unaudited financial results for the fourth quarter and full year ended december 31, 2024. preliminary fourth quarter 2024 financial results revenue is expected to be between $85 million and $86 million, an increase of approximately 30% year-over-year. testing services revenue is expected to be between $62.5 million and $63.5 million, an increase of approximately 35% year-over-y.
CDNA Ratings Summary
CDNA Quant Ranking